H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITURE; INC.
发明人:
Marco Davila
申请号：
US16346226
公开号：
US20190262400A1
申请日:
2017.10.31
申请国别(地区):
US
年份:
2019
代理人:
摘要：
Disclosed herein are methods of expanding immune cells for immunotherapy using artificial antigen presenting cells (aAPCs) having on their surface antibodies or ligands that bind molecules of both the T cell activation pathway and T cell costimulation pathway. The disclosed aAPCs can also secrete antibodies that bind molecules of the T cell inhibitory pathway. For example, anti-CD3 scFv on the surface of the aAPCs can bind and activate T cells, while anti-CD28 scFv and 4-1BBL on the surface of the aAPCs can provide dual co-stimulation for the T cells resulting in decreased levels of the markers CD25, TIM3, LAG3, and PD1. For example, blocking PD1/PDL1 ligation can limit suppression that is mediated by the tumor microenvironment. This is a less costly and more efficient alternative to peripheral blood mononuclear cells (PBMCs) and cytokine treatments that result in better quality T cell for adoptive transfer back into patients.
